Genenta Science S.p.A. GNTA

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

Last close —

Market cap —

52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—

P/E—

P/FCF—

EV/EBITDA—

Dividend yield—

Diluted EPS—

Annual financial statements

Income statement

Fiscal year	FY2025	FY2024	FY2023	FY2022	FY2021
Shares, diluted (wtd. avg.)	19.7M	18.3M	18.2M	18.2M	15.1M

Balance sheet

Fiscal year	FY2025	FY2024	FY2023	FY2022	FY2021
Cash and equivalents	—	—	—	—	$25.7M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-014387.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)

Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity

Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks

R&D
Goodwill
Receivables
Cash and equivalents

Fiscal year	FY2021	FY2022	FY2023	FY2024	FY2025
R&D	—	—	—	—	—
Goodwill	—	—	—	—	—
Receivables	—	—	—	—	—
Cash and equivalents	$25.7M	—	—	—	—

Others in SIC 2836

Ticker	Company	Market cap	P/E	Revenue growth
AMGN	AMGEN INC	$236.38B	30.7x	10.0%
GILD	GILEAD SCIENCES, INC.	$187.23B	22.3x	2.4%
MRNA	Moderna, Inc.	$58.11B	—	-39.9%
RVMD	Revolution Medicines, Inc.	$45.01B	—	—
BIIB	BIOGEN INC.	$32.60B	25.1x	2.2%
SCNI	Scinai Immunotherapeutics Ltd.	$25.80B	—	99.2%
NBIX	NEUROCRINE BIOSCIENCES INC	$15.82B	33.3x	21.4%
EXEL	EXELIXIS, INC.	$14.62B	21.2x	7.0%